OJ L 33, 8.2.2003, p. 30.

OJ L 203, 21.7.1998, p. 14.

http://www.legislation.gov.uk/eudr/2004/33/contentsCommission Directive 2004/33/EC of 22 March 2004 implementing Directive 2002/98/EC of the European Parliament and of the Council as regards certain technical requirements for blood and blood components (Text with EEA relevance)Commission Directive 2004/33/ECCommission Directive 2004/33/EC of 22 March 2004 implementing Directive 2002/98/EC of the European Parliament and of the Council as regards certain technical requirements for blood and blood components (Text with EEA relevance)2020-12-10King's Printer of Acts of Parliamenthttps://webarchive.nationalarchives.gov.uk/eu-exit/https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX:02004L0033-20150109texttext/xmlen2015-01-09Article 1DefinitionsArticle 2Provision of information to prospective donorsArticle 3Information required from donorsArticle 4Eligibility of donorsArticle 5Storage, transport and distribution conditions for blood and blood componentsArticle 6Quality and safety requirements for blood and blood componentsArticle 7Autologous donationsArticle 8ValidationArticle 9TranspositionArticle 10Entry into forceArticle 11AddresseesANNEX IDEFINITIONS1.‘Autologous donation’ means blood and blood components collected from an...2.‘Allogeneic donation’ means blood and blood components collected from an...3.‘Validation’ means the establishment of documented and objective evidence that...4.‘Whole blood’ means a single blood donation. 5.‘Cryopreservation’ means prolongation of the storage life of blood components...6.‘Plasma’ means the liquid portion of the blood in which...7.‘Cryoprecipitate’ means a plasma component prepared from plasma, fresh-frozen, by...8.‘Washed’ means a process of removing plasma or storage medium...9.‘Red cells’ means the red cells from a single whole...10.‘Red cells, buffy coat removed’ means the red cells from...11.‘Red cells, leucocyte-depleted’ means the red cells from a single...12.‘Red cells in additive solution’ means the red cells from...13.‘Additive solution’ means a solution specifically formulated to maintain beneficial...14.‘Red cells, buffy coat removed, in additive solution’ means the...15.‘Buffy coat’ means a blood component prepared by centrifugation of...16.‘Red cells, leucocyte-depleted, in additive solution’ means the red cells...17.‘Red cells, apheresis’ means the red cells from an apheresis...18.‘Apheresis’ means a method of obtaining one or more blood...19.‘Platelets, apheresis’ means a concentrated suspension of blood platelets obtained...20.‘Platelets, apheresis, leucocyte-depleted’ means a concentrated suspension of blood platelets,...21.‘Platelets, recovered, pooled’ means a concentrated suspension of blood platelets,...22.‘Platelets, recovered, pooled, leucocyte-depleted’ means a concentrated suspension of blood...23.‘Platelets, recovered, single unit’ means a concentrated suspension of blood...24.‘Platelets, recovered, single unit, leucocyte-depleted’ means a concentrated suspension of...25.‘Plasma, fresh-frozen’ means the supernatant plasma separated from a whole...26.‘Plasma, cryoprecipitate-depleted for transfusion’ means a plasma component prepared from...27.‘Granulocytes, apheresis’ means a concentrated suspension of granulocytes obtained by...28.‘Statistical process control’ means a method of quality control of...ANNEX IIINFORMATION REQUIREMENTSPART AInformation to be provided to prospective donors of blood or blood components1.Accurate educational materials, which are understandable for members of the...2.For both allogeneic and autologous donations, the reasons for requiring...3.Information on the protection of personal data: no unauthorised disclosure...4.The reasons why individuals are not to make donations which...5.Specific information on the nature of the procedures involved either...6.Information on the option for donors to change their mind...7.The reasons why it is important that donors inform the...8.Information on the responsibility of the blood establishment to inform...9.Information why unused autologous blood and blood components will be...10.Information that test results detecting markers for viruses, such as...11.Information on the opportunity for donors to ask questions at...PART BInformation to be obtained from donors by blood establishments at every donation1.Identification of the donor 2.Health and medical history of the donor 3.Signature of the donor ANNEX IIIELIGIBILITY CRITERIA FOR DONORS OF WHOLE BLOOD AND BLOOD COMPONENTS1.ACCEPTANCE CRITERIA FOR DONORS OF WHOLE BLOOD AND BLOOD COMPONENTS...1.1.Age and body weight of donors 1.2.Haemoglobin levels in donor's blood 1.3.Protein levels in donor's blood 1.4.Platelet levels in donor's blood 2.DEFERRAL CRITERIA FOR DONORS OF WHOLE BLOOD AND BLOOD COMPONENTS...2.1.Permanent deferral criteria for donors of allogeneic donations 2.2.Temporary deferral criteria for donors of allogeneic donations 2.2.1.Infections Duration of deferral period 2.2.2.Exposure to risk of acquiring a transfusion-transmissible infection 2.2.3.Vaccination 2.2.4.Other temporary deferrals 2.3.Deferral for particular epidemiological situations 2.4.Deferral criteria for donors of autologous donations ANNEX IVSTORAGE, TRANSPORT AND DISTRIBUTION CONDITIONS FOR BLOOD AND BLOOD COMPONENTS1.STORAGE 1.1.Liquid storage 1.2.Cryopreservation 2.TRANSPORT AND DISTRIBUTION 3.ADDITIONAL REQUIREMENTS FOR AUTOLOGOUS DONATIONS 3.1.Autologous blood and blood components must be clearly identified as...3.2.Autologous blood and blood components must be labelled as required...ANNEX VQUALITY AND SAFETY REQUIREMENTS FOR BLOOD AND BLOOD COMPONENTS1.THE BLOOD COMPONENTS 2.QUALITY CONTROL REQUIREMENTS FOR BLOOD AND BLOOD COMPONENTS 2.1.Blood and blood components must comply with the following technical...2.2.Appropriate bacteriological control of the collection and manufacturing process must...2.3.Member States must take all necessary measures to ensure that...2.4.For autologous donations, the measures marked with an asterisk (*)...

Commission Directive 2004/33/EC

of 22 March 2004

implementing Directive 2002/98/EC of the European Parliament and of the Council as regards certain technical requirements for blood and blood components

(Text with EEA relevance)

THE COMMISSION OF THE EUROPEAN COMMUNITIES,

Having regard to the Treaty establishing the European Community,

Having regard to Directive 2002/98/EC of the European Parliament and of the Council of 27 January 2003 setting standards of quality and safety for the collection, testing, processing, storage and distribution of human blood and blood components and amending Directive 2001/83/EC, and in particular points (b) to (g) of the second paragraph of Article 29 thereof,

Whereas:

(1)

Directive 2002/98/EC lays down standards of quality and safety for the collection and testing of human blood and blood components, whatever their intended purpose, and for their processing, storage and distribution when intended for transfusion so as to ensure a high level of human health protection.

(2)

In order to prevent the transmission of diseases by blood and blood components and to ensure an equivalent level of quality and safety, Directive 2002/98/EC calls for the establishment of specific technical requirements.

(3)

This Directive lays down those technical requirements, which take account of Council Recommendation 98/463/EC of 29 June 1998 on the suitability of blood and plasma donors and the screening of donated blood in the European Community, certain recommendations of the Council of Europe, the opinion of the Scientific Committee for Medicinal Products and Medical Devices, the monographs of the European Pharmacopoeia, particularly in respect of blood or blood components as a starting material for the manufacture of proprietary medicinal products and recommendations of the World Health Organisation (WHO), as well as international experience in this field.

(4)

Blood and blood components imported from third countries, including those used as starting material/raw material for the manufacture of medicinal products derived from human blood and human plasma, should meet the quality and safety requirements set out in this Directive.

(5)

With regard to blood and blood components collected for the sole purpose of, and exclusive use in, autologous transfusion (autologous donation), specific technical requirements should be laid down, as required by Article 2(2) of Directive 2002/98/EC. Such donations should be clearly identified and kept separate from other donations to ensure that they are not used for transfusion to other patients.

(6)

It is necessary to determine common definitions for technical terminology in order to ensure the consistent implementation of Directive 2002/98/EC.

(7)

The measures provided for in this Directive are in accordance with the opinion of the Committee set up by Directive 2002/98/EC,

HAS ADOPTED THIS DIRECTIVE:

This XML file does not appear to have any style information associated with it. The document tree is shown below.
<akomaNtoso xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://docs.oasis-open.org/legaldocml/ns/akn/3.0" xsi:schemaLocation="http://docs.oasis-open.org/legaldocml/ns/akn/3.0 http://docs.oasis-open.org/legaldocml/akn-core/v1.0/cos01/part2-specs/schemas/akomantoso30.xsd">
<act name="EuropeanUnionDirective">
<meta>
<identification source="#source">
<FRBRWork>
<FRBRthis value="http://www.legislation.gov.uk/id/eudr/2004/33/contents"/>
<FRBRuri value="http://www.legislation.gov.uk/id/eudr/2004/33/contents"/>
<FRBRdate date="2004-03-22" name="adopted"/>
<FRBRauthor href=""/>
<FRBRcountry value="EU"/>
<FRBRnumber value="33"/>
<FRBRname value="Directive (EU) 2004/33"/>
<FRBRprescriptive value="true"/>
</FRBRWork>
<FRBRExpression>
<FRBRthis value="http://www.legislation.gov.uk/eudr/2004/33/contents"/>
<FRBRuri value="http://www.legislation.gov.uk/eudr/2004/33/contents"/>
<FRBRdate date="2015-01-09" name="validFrom"/>
<FRBRauthor href="#source"/>
<FRBRlanguage language="eng"/>
</FRBRExpression>
<FRBRManifestation>
<FRBRthis value="http://www.legislation.gov.uk/eudr/2004/33/contents/data.akn"/>
<FRBRuri value="http://www.legislation.gov.uk/eudr/2004/33/contents/data.akn"/>
<FRBRdate date="2024-11-19Z" name="transform"/>
<FRBRauthor href="http://www.legislation.gov.uk"/>
<FRBRformat value="application/akn+xml"/>
</FRBRManifestation>
</identification>
<lifecycle source="#source">
<eventRef date="2004-03-22" type="generation" eId="enacted-date" source="#source"/>
<eventRef date="2011-04-13" type="amendment" source="#source"/>
<eventRef date="2015-01-09" type="amendment" source="#source"/>
<eventRef date="2011-04-13" eId="effective-date-1" source="#source"/>
<eventRef date="2015-01-09" eId="effective-date-2" source="#source"/>
</lifecycle>
<analysis source="#source">
<restrictions source="#source">
<restriction refersTo="#e+w+s+ni" type="jurisdiction"/>
<restriction href="#article-1" refersTo="#e+w+s+ni" type="jurisdiction"/>
<restriction href="#article-2" refersTo="#e+w+s+ni" type="jurisdiction"/>
<restriction href="#article-3" refersTo="#e+w+s+ni" type="jurisdiction"/>
<restriction href="#article-4" refersTo="#e+w+s+ni" type="jurisdiction"/>
<restriction href="#article-5" refersTo="#e+w+s+ni" type="jurisdiction"/>
<restriction href="#article-6" refersTo="#e+w+s+ni" type="jurisdiction"/>
<restriction href="#article-7" refersTo="#e+w+s+ni" type="jurisdiction"/>
<restriction href="#article-8" refersTo="#e+w+s+ni" type="jurisdiction"/>
<restriction href="#article-9" refersTo="#e+w+s+ni" type="jurisdiction"/>
<restriction href="#article-10" refersTo="#e+w+s+ni" type="jurisdiction"/>
<restriction href="#article-11" refersTo="#e+w+s+ni" type="jurisdiction"/>
<restriction href="#d4e731" refersTo="#e+w+s+ni" type="jurisdiction"/>
<restriction href="#d4e732" refersTo="#e+w+s+ni" type="jurisdiction"/>
<restriction href="#d4e737" refersTo="#e+w+s+ni" type="jurisdiction"/>
<restriction href="#d4e742" refersTo="#e+w+s+ni" type="jurisdiction"/>
<restriction href="#d4e747" refersTo="#e+w+s+ni" type="jurisdiction"/>
<restriction href="#d4e752" refersTo="#e+w+s+ni" type="jurisdiction"/>
<restriction href="#d4e757" refersTo="#e+w+s+ni" type="jurisdiction"/>
<restriction href="#d4e762" refersTo="#e+w+s+ni" type="jurisdiction"/>
<restriction href="#d4e767" refersTo="#e+w+s+ni" type="jurisdiction"/>
<restriction href="#d4e772" refersTo="#e+w+s+ni" type="jurisdiction"/>
<restriction href="#d4e777" refersTo="#e+w+s+ni" type="jurisdiction"/>
<restriction href="#d4e783" refersTo="#e+w+s+ni" type="jurisdiction"/>
<restriction href="#d4e788" refersTo="#e+w+s+ni" type="jurisdiction"/>
<restriction href="#d4e793" refersTo="#e+w+s+ni" type="jurisdiction"/>
<restriction href="#d4e798" refersTo="#e+w+s+ni" type="jurisdiction"/>
<restriction href="#d4e803" refersTo="#e+w+s+ni" type="jurisdiction"/>
<restriction href="#d4e808" refersTo="#e+w+s+ni" type="jurisdiction"/>
<restriction href="#d4e813" refersTo="#e+w+s+ni" type="jurisdiction"/>
<restriction href="#d4e818" refersTo="#e+w+s+ni" type="jurisdiction"/>
<restriction href="#d4e823" refersTo="#e+w+s+ni" type="jurisdiction"/>
<restriction href="#d4e828" refersTo="#e+w+s+ni" type="jurisdiction"/>
<restriction href="#d4e833" refersTo="#e+w+s+ni" type="jurisdiction"/>
<restriction href="#d4e839" refersTo="#e+w+s+ni" type="jurisdiction"/>
<restriction href="#d4e844" refersTo="#e+w+s+ni" type="jurisdiction"/>
<restriction href="#d4e849" refersTo="#e+w+s+ni" type="jurisdiction"/>
<restriction href="#d4e854" refersTo="#e+w+s+ni" type="jurisdiction"/>
<restriction href="#d4e859" refersTo="#e+w+s+ni" type="jurisdiction"/>
<restriction href="#d4e864" refersTo="#e+w+s+ni" type="jurisdiction"/>
<restriction href="#d4e869" refersTo="#e+w+s+ni" type="jurisdiction"/>
<restriction href="#d4e874" refersTo="#e+w+s+ni" type="jurisdiction"/>
<restriction href="#d4e879" refersTo="#e+w+s+ni" type="jurisdiction"/>
<restriction href="#d4e884" refersTo="#e+w+s+ni" type="jurisdiction"/>
<restriction href="#d4e889" refersTo="#e+w+s+ni" type="jurisdiction"/>
<restriction href="#d4e894" refersTo="#e+w+s+ni" type="jurisdiction"/>
<restriction href="#d4e899" refersTo="#e+w+s+ni" type="jurisdiction"/>
<restriction href="#d4e904" refersTo="#e+w+s+ni" type="jurisdiction"/>
<restriction href="#d4e909" refersTo="#e+w+s+ni" type="jurisdiction"/>
<restriction href="#d4e914" refersTo="#e+w+s+ni" type="jurisdiction"/>
<restriction href="#d4e919" refersTo="#e+w+s+ni" type="jurisdiction"/>
<restriction href="#d4e924" refersTo="#e+w+s+ni" type="jurisdiction"/>
<restriction href="#d4e929" refersTo="#e+w+s+ni" type="jurisdiction"/>
<restriction href="#d4e935" refersTo="#e+w+s+ni" type="jurisdiction"/>
<restriction href="#d4e940" refersTo="#e+w+s+ni" type="jurisdiction"/>
<restriction href="#d4e945" refersTo="#e+w+s+ni" type="jurisdiction"/>
<restriction href="#d4e950" refersTo="#e+w+s+ni" type="jurisdiction"/>
<restriction href="#d4e955" refersTo="#e+w+s+ni" type="jurisdiction"/>
<restriction href="#d4e960" refersTo="#e+w+s+ni" type="jurisdiction"/>
<restriction href="#d4e965" refersTo="#e+w+s+ni" type="jurisdiction"/>
<restriction href="#d4e970" refersTo="#e+w+s+ni" type="jurisdiction"/>
<restriction href="#d4e975" refersTo="#e+w+s+ni" type="jurisdiction"/>
<restriction href="#d4e980" refersTo="#e+w+s+ni" type="jurisdiction"/>
<restriction href="#d4e985" refersTo="#e+w+s+ni" type="jurisdiction"/>
<restriction href="#d4e990" refersTo="#e+w+s+ni" type="jurisdiction"/>
<restriction href="#d4e995" refersTo="#e+w+s+ni" type="jurisdiction"/>
<restriction href="#d4e1000" refersTo="#e+w+s+ni" type="jurisdiction"/>
<restriction href="#d4e1005" refersTo="#e+w+s+ni" type="jurisdiction"/>
<restriction href="#d4e1010" refersTo="#e+w+s+ni" type="jurisdiction"/>
<restriction href="#d4e1015" refersTo="#e+w+s+ni" type="jurisdiction"/>
<restriction href="#d4e1018" refersTo="#e+w+s+ni" type="jurisdiction"/>
<restriction href="#d4e1023" refersTo="#e+w+s+ni" type="jurisdiction"/>
<restriction href="#d4e1028" refersTo="#e+w+s+ni" type="jurisdiction"/>
<restriction href="#d4e1033" refersTo="#e+w+s+ni" type="jurisdiction"/>
<restriction href="#d4e1038" refersTo="#e+w+s+ni" type="jurisdiction"/>
<restriction href="#d4e1043" refersTo="#e+w+s+ni" type="jurisdiction"/>
<restriction href="#d4e1048" refersTo="#e+w+s+ni" type="jurisdiction"/>
<restriction href="#d4e1053" refersTo="#e+w+s+ni" type="jurisdiction"/>
<restriction href="#d4e1058" refersTo="#e+w+s+ni" type="jurisdiction"/>
<restriction href="#d4e1063" refersTo="#e+w+s+ni" type="jurisdiction"/>
<restriction href="#d4e1068" refersTo="#e+w+s+ni" type="jurisdiction"/>
<restriction href="#d4e1073" refersTo="#e+w+s+ni" type="jurisdiction"/>
<restriction href="#d4e1078" refersTo="#e+w+s+ni" type="jurisdiction"/>
<restriction href="#d4e1083" refersTo="#e+w+s+ni" type="jurisdiction"/>
<restriction href="#d4e1088" refersTo="#e+w+s+ni" type="jurisdiction"/>
<restriction href="#d4e1093" refersTo="#e+w+s+ni" type="jurisdiction"/>
<restriction href="#d4e1098" refersTo="#e+w+s+ni" type="jurisdiction"/>
<restriction href="#d4e1103" refersTo="#e+w+s+ni" type="jurisdiction"/>
<restriction href="#d4e1108" refersTo="#e+w+s+ni" type="jurisdiction"/>
<restriction href="#d4e1113" refersTo="#e+w+s+ni" type="jurisdiction"/>
<restriction href="#d4e1119" refersTo="#e+w+s+ni" type="jurisdiction"/>
</restrictions>
</analysis>
<temporalData source="#source">
<temporalGroup eId="period1">
<timeInterval start="#effective-date-1" refersTo="#period-concept1"/>
</temporalGroup>
<temporalGroup eId="period2">
<timeInterval start="#effective-date-2" refersTo="#period-concept2"/>
</temporalGroup>
</temporalData>
<references source="#source">
<TLCOrganization eId="source" href="http://www.legislation.gov.uk/id/publisher/KingsOrQueensPrinterOfActsOfParliament" showAs="King's Printer of Acts of Parliament"/>
<TLCLocation eId="e+w+s+ni" href="/ontology/jurisdictions/uk.EnglandWalesScotlandNorthernIreland" showAs="England, Wales, Scotland, Northern Ireland"/>
<TLCConcept eId="period-concept1" href="/ontology/time/2011.04.13" showAs="since 2011-04-13"/>
<TLCConcept eId="period-concept2" href="/ontology/time/2015.01.09" showAs="since 2015-01-09"/>
</references>
<notes source="#source">
<note class="footnote" eId="f00001">
<p>
<ref href="https://webarchive.nationalarchives.gov.uk/eu-exit/https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=uriserv:OJ.L_.2003.033.01.0030.01.ENG">OJ L 33, 8.2.2003, p. 30</ref>
.
</p>
</note>
<note class="footnote" eId="f00002">
<p>
<ref href="https://webarchive.nationalarchives.gov.uk/eu-exit/https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=uriserv:OJ.L_.1998.203.01.0014.01.ENG">OJ L 203, 21.7.1998, p. 14</ref>
.
</p>
</note>
</notes>
<proprietary xmlns:ukl="http://www.legislation.gov.uk/namespaces/legislation" xmlns:ukm="http://www.legislation.gov.uk/namespaces/metadata" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dct="http://purl.org/dc/terms/" xmlns:atom="http://www.w3.org/2005/Atom" source="#source">
<ukl:RestrictStartDate value="2015-01-09"/>
<dc:identifier>http://www.legislation.gov.uk/eudr/2004/33/contents</dc:identifier>
<dc:title>Commission Directive 2004/33/EC of 22 March 2004 implementing Directive 2002/98/EC of the European Parliament and of the Council as regards certain technical requirements for blood and blood components (Text with EEA relevance)</dc:title>
<dct:alternative>Commission Directive 2004/33/EC</dct:alternative>
<dc:description>Commission Directive 2004/33/EC of 22 March 2004 implementing Directive 2002/98/EC of the European Parliament and of the Council as regards certain technical requirements for blood and blood components (Text with EEA relevance)</dc:description>
<dc:modified>2020-12-10</dc:modified>
<dc:publisher>King's Printer of Acts of Parliament</dc:publisher>
<dc:source>https://webarchive.nationalarchives.gov.uk/eu-exit/https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX:02004L0033-20150109</dc:source>
<dc:type>text</dc:type>
<dc:format>text/xml</dc:format>
<dc:language>en</dc:language>
<dct:valid>2015-01-09</dct:valid>
<atom:link rel="self" href="http://www.legislation.gov.uk/eudr/2004/33/contents/data.xml" type="application/xml"/>
<atom:link rel="http://www.legislation.gov.uk/def/navigation/resources" href="http://www.legislation.gov.uk/eudr/2004/33/resources" title="More Resources"/>
<atom:link rel="http://www.legislation.gov.uk/def/navigation/act" href="http://www.legislation.gov.uk/eudr/2004/33" title="whole act"/>
<atom:link rel="http://www.legislation.gov.uk/def/navigation/introduction" href="http://www.legislation.gov.uk/eudr/2004/33/introduction" title="introduction"/>
<atom:link rel="http://www.legislation.gov.uk/def/navigation/body" href="http://www.legislation.gov.uk/eudr/2004/33/body" title="body"/>
<atom:link rel="http://www.legislation.gov.uk/def/navigation/annexes" href="http://www.legislation.gov.uk/eudr/2004/33/annexes" title="annexes"/>
<atom:link rel="http://www.legislation.gov.uk/def/date/euexitday" href="http://www.legislation.gov.uk/eudr/2004/33/contents/2020-01-31" title="2020-01-31"/>
<atom:link rel="http://www.legislation.gov.uk/def/date/euexitTransitionEnd" href="http://www.legislation.gov.uk/eudr/2004/33/contents/2020-12-31" title="2020-12-31"/>
<atom:link rel="alternate" type="application/akn+xml" href="http://www.legislation.gov.uk/eudr/2004/33/contents/data.akn" title="AKN"/>
<atom:link rel="alternate" type="application/xhtml+xml" href="http://www.legislation.gov.uk/eudr/2004/33/contents/data.xht" title="HTML snippet"/>
<atom:link rel="alternate" type="text/html" href="http://www.legislation.gov.uk/eudr/2004/33/contents/data.htm" title="Website (XHTML) Default View"/>
<atom:link rel="alternate" type="text/csv" href="http://www.legislation.gov.uk/eudr/2004/33/contents/data.csv" title="CSV"/>
<atom:link rel="alternate" type="application/pdf" href="http://www.legislation.gov.uk/eudr/2004/33/contents/data.pdf" title="PDF"/>
<atom:link rel="alternate" type="application/akn+xhtml" href="http://www.legislation.gov.uk/eudr/2004/33/contents/data.html" title="HTML5 snippet"/>
<atom:link rel="http://purl.org/dc/terms/tableOfContents" hreflang="en" href="http://www.legislation.gov.uk/eudr/2004/33/contents" title="Table of Contents"/>
<atom:link rel="http://purl.org/dc/terms/replaces" href="http://www.legislation.gov.uk/eudr/2004/33/contents/2011-04-13" title="2011-04-13"/>
<atom:link rel="http://purl.org/dc/terms/hasVersion" href="http://www.legislation.gov.uk/eudr/2004/33/contents/adopted" title="adopted"/>
<atom:link rel="http://purl.org/dc/terms/hasVersion" href="http://www.legislation.gov.uk/eudr/2004/33/contents/2011-04-13" title="2011-04-13"/>
<atom:link rel="http://purl.org/dc/terms/hasVersion" href="http://www.legislation.gov.uk/eudr/2004/33/contents/2015-01-09" title="2015-01-09"/>
<ukm:EUMetadata>
<ukm:DocumentClassification>
<ukm:DocumentCategory Value="euretained"/>
<ukm:DocumentMainType Value="EuropeanUnionDirective"/>
<ukm:DocumentStatus Value="revised"/>
</ukm:DocumentClassification>
<ukm:Year Value="2004"/>
<ukm:Number Value="33"/>
<ukm:EURLexIdentifiers>
<ukm:Cellar Value="436b1fdb-26d0-4d2f-9ecd-8c19e491db6c"/>
<ukm:CELEX Value="02004L0033-20150109"/>
<ukm:ELI Value="dir:2004:33:2015-01-09"/>
</ukm:EURLexIdentifiers>
<ukm:EnactmentDate Date="2004-03-22"/>
<ukm:EURLexModified Date="2019-04-17T13:31:32Z"/>
<ukm:EURLexExtracted Date="2019-04-17T15:35:57Z"/>
<ukm:XMLGenerated Date="2020-12-10T20:02:02Z"/>
<ukm:XMLImported Date="2020-12-10T20:55:46Z"/>
</ukm:EUMetadata>
<ukm:Alternatives>
<ukm:Alternative URI="http://www.legislation.gov.uk/eudr/2004/33/pdfs/eudr_20040033_adopted_en.pdf" Date="2004-03-22" Size="204853"/>
<ukm:Alternative URI="http://www.legislation.gov.uk/eudr/2004/33/pdfs/eudr_20040033_2011-04-13_en.pdf" Date="2011-04-13" Size="770332" Revised="2011-04-13"/>
<ukm:Alternative URI="http://www.legislation.gov.uk/eudr/2004/33/pdfs/eudr_20040033_2015-01-09_en.pdf" Date="2015-01-09" Size="293300" Revised="2015-01-09"/>
</ukm:Alternatives>
<ukm:Statistics>
<ukm:TotalParagraphs Value="94"/>
<ukm:BodyParagraphs Value="11"/>
<ukm:ScheduleParagraphs Value="83"/>
<ukm:AttachmentParagraphs Value="0"/>
<ukm:TotalImages Value="0"/>
</ukm:Statistics>
</proprietary>
</meta>
<coverPage>
<toc>
<tocItem href="http://www.legislation.gov.uk/eudr/2004/33/article/1" level="1" class="item" period="#period1">
<inline name="tocNum">Article 1</inline>
<inline name="tocHeading">Definitions</inline>
</tocItem>
<tocItem href="http://www.legislation.gov.uk/eudr/2004/33/article/2" level="1" class="item" period="#period1">
<inline name="tocNum">Article 2</inline>
<inline name="tocHeading">Provision of information to prospective donors</inline>
</tocItem>
<tocItem href="http://www.legislation.gov.uk/eudr/2004/33/article/3" level="1" class="item" period="#period1">
<inline name="tocNum">Article 3</inline>
<inline name="tocHeading">Information required from donors</inline>
</tocItem>
<tocItem href="http://www.legislation.gov.uk/eudr/2004/33/article/4" level="1" class="item" period="#period1">
<inline name="tocNum">Article 4</inline>
<inline name="tocHeading">Eligibility of donors</inline>
</tocItem>
<tocItem href="http://www.legislation.gov.uk/eudr/2004/33/article/5" level="1" class="item" period="#period1">
<inline name="tocNum">Article 5</inline>
<inline name="tocHeading">Storage, transport and distribution conditions for blood and blood components</inline>
</tocItem>
<tocItem href="http://www.legislation.gov.uk/eudr/2004/33/article/6" level="1" class="item" period="#period1">
<inline name="tocNum">Article 6</inline>
<inline name="tocHeading">Quality and safety requirements for blood and blood components</inline>
</tocItem>
<tocItem href="http://www.legislation.gov.uk/eudr/2004/33/article/7" level="1" class="item" period="#period1">
<inline name="tocNum">Article 7</inline>
<inline name="tocHeading">Autologous donations</inline>
</tocItem>
<tocItem href="http://www.legislation.gov.uk/eudr/2004/33/article/8" level="1" class="item" period="#period1">
<inline name="tocNum">Article 8</inline>
<inline name="tocHeading">Validation</inline>
</tocItem>
<tocItem href="http://www.legislation.gov.uk/eudr/2004/33/article/9" level="1" class="item" period="#period1">
<inline name="tocNum">Article 9</inline>
<inline name="tocHeading">Transposition</inline>
</tocItem>
<tocItem href="http://www.legislation.gov.uk/eudr/2004/33/article/10" level="1" class="item" period="#period1">
<inline name="tocNum">Article 10</inline>
<inline name="tocHeading">Entry into force</inline>
</tocItem>
<tocItem href="http://www.legislation.gov.uk/eudr/2004/33/article/11" level="1" class="item" period="#period1">
<inline name="tocNum">Article 11</inline>
<inline name="tocHeading">Addressees</inline>
</tocItem>
<tocItem href="" level="1" class="schedules" period="#period2"/>
<tocItem href="http://www.legislation.gov.uk/eudr/2004/33/annex/I" level="2" class="schedule" period="#period1">
<inline name="tocNum">ANNEX I</inline>
<inline name="tocHeading">DEFINITIONS</inline>
</tocItem>
<inline name="tocNum">1.</inline>
<inline name="tocHeading">‘Autologous donation’ means blood and blood components collected from an...</inline>
<inline name="tocNum">2.</inline>
<inline name="tocHeading">‘Allogeneic donation’ means blood and blood components collected from an...</inline>
<inline name="tocNum">3.</inline>
<inline name="tocHeading">‘Validation’ means the establishment of documented and objective evidence that...</inline>
<inline name="tocNum">4.</inline>
<inline name="tocHeading">‘Whole blood’ means a single blood donation. </inline>
<inline name="tocNum">5.</inline>
<inline name="tocHeading">‘Cryopreservation’ means prolongation of the storage life of blood components...</inline>
<inline name="tocNum">6.</inline>
<inline name="tocHeading">‘Plasma’ means the liquid portion of the blood in which...</inline>
<inline name="tocNum">7.</inline>
<inline name="tocHeading">‘Cryoprecipitate’ means a plasma component prepared from plasma, fresh-frozen, by...</inline>
<inline name="tocNum">8.</inline>
<inline name="tocHeading">‘Washed’ means a process of removing plasma or storage medium...</inline>
<inline name="tocNum">9.</inline>
<inline name="tocHeading">‘Red cells’ means the red cells from a single whole...</inline>
<inline name="tocNum">10.</inline>
<inline name="tocHeading">‘Red cells, buffy coat removed’ means the red cells from...</inline>
<inline name="tocNum">11.</inline>
<inline name="tocHeading">‘Red cells, leucocyte-depleted’ means the red cells from a single...</inline>
<inline name="tocNum">12.</inline>
<inline name="tocHeading">‘Red cells in additive solution’ means the red cells from...</inline>
<inline name="tocNum">13.</inline>
<inline name="tocHeading">‘Additive solution’ means a solution specifically formulated to maintain beneficial...</inline>
<inline name="tocNum">14.</inline>
<inline name="tocHeading">‘Red cells, buffy coat removed, in additive solution’ means the...</inline>
<inline name="tocNum">15.</inline>
<inline name="tocHeading">‘Buffy coat’ means a blood component prepared by centrifugation of...</inline>
<inline name="tocNum">16.</inline>
<inline name="tocHeading">‘Red cells, leucocyte-depleted, in additive solution’ means the red cells...</inline>
<inline name="tocNum">17.</inline>
<inline name="tocHeading">‘Red cells, apheresis’ means the red cells from an apheresis...</inline>
<inline name="tocNum">18.</inline>
<inline name="tocHeading">‘Apheresis’ means a method of obtaining one or more blood...</inline>
<inline name="tocNum">19.</inline>
<inline name="tocHeading">‘Platelets, apheresis’ means a concentrated suspension of blood platelets obtained...</inline>
<inline name="tocNum">20.</inline>
<inline name="tocHeading">‘Platelets, apheresis, leucocyte-depleted’ means a concentrated suspension of blood platelets,...</inline>
<inline name="tocNum">21.</inline>
<inline name="tocHeading">‘Platelets, recovered, pooled’ means a concentrated suspension of blood platelets,...</inline>
<inline name="tocNum">22.</inline>
<inline name="tocHeading">‘Platelets, recovered, pooled, leucocyte-depleted’ means a concentrated suspension of blood...</inline>
<inline name="tocNum">23.</inline>
<inline name="tocHeading">‘Platelets, recovered, single unit’ means a concentrated suspension of blood...</inline>
<inline name="tocNum">24.</inline>
<inline name="tocHeading">‘Platelets, recovered, single unit, leucocyte-depleted’ means a concentrated suspension of...</inline>
<inline name="tocNum">25.</inline>
<inline name="tocHeading">‘Plasma, fresh-frozen’ means the supernatant plasma separated from a whole...</inline>
<inline name="tocNum">26.</inline>
<inline name="tocHeading">‘Plasma, cryoprecipitate-depleted for transfusion’ means a plasma component prepared from...</inline>
<inline name="tocNum">27.</inline>
<inline name="tocHeading">‘Granulocytes, apheresis’ means a concentrated suspension of granulocytes obtained by...</inline>
<inline name="tocNum">28.</inline>
<inline name="tocHeading">‘Statistical process control’ means a method of quality control of...</inline>
<tocItem href="http://www.legislation.gov.uk/eudr/2004/33/annex/II" level="2" class="schedule" period="#period1">
<inline name="tocNum">ANNEX II</inline>
<inline name="tocHeading">INFORMATION REQUIREMENTS</inline>
</tocItem>
<inline name="tocNum">PART A</inline>
<inline name="tocHeading">Information to be provided to prospective donors of blood or blood components</inline>
<inline name="tocNum">1.</inline>
<inline name="tocHeading">Accurate educational materials, which are understandable for members of the...</inline>
<inline name="tocNum">2.</inline>
<inline name="tocHeading">For both allogeneic and autologous donations, the reasons for requiring...</inline>
<inline name="tocNum">3.</inline>
<inline name="tocHeading">Information on the protection of personal data: no unauthorised disclosure...</inline>
<inline name="tocNum">4.</inline>
<inline name="tocHeading">The reasons why individuals are not to make donations which...</inline>
<inline name="tocNum">5.</inline>
<inline name="tocHeading">Specific information on the nature of the procedures involved either...</inline>
<inline name="tocNum">6.</inline>
<inline name="tocHeading">Information on the option for donors to change their mind...</inline>
<inline name="tocNum">7.</inline>
<inline name="tocHeading">The reasons why it is important that donors inform the...</inline>
<inline name="tocNum">8.</inline>
<inline name="tocHeading">Information on the responsibility of the blood establishment to inform...</inline>
<inline name="tocNum">9.</inline>
<inline name="tocHeading">Information why unused autologous blood and blood components will be...</inline>
<inline name="tocNum">10.</inline>
<inline name="tocHeading">Information that test results detecting markers for viruses, such as...</inline>
<inline name="tocNum">11.</inline>
<inline name="tocHeading">Information on the opportunity for donors to ask questions at...</inline>
<inline name="tocNum">PART B</inline>
<inline name="tocHeading">Information to be obtained from donors by blood establishments at every donation</inline>
<inline name="tocNum">1.</inline>
<inline name="tocHeading">Identification of the donor </inline>
<inline name="tocNum">2.</inline>
<inline name="tocHeading">Health and medical history of the donor </inline>
<inline name="tocNum">3.</inline>
<inline name="tocHeading">Signature of the donor </inline>
<tocItem href="http://www.legislation.gov.uk/eudr/2004/33/annex/III" level="2" class="schedule" period="#period2">
<inline name="tocNum">ANNEX III</inline>
<inline name="tocHeading">ELIGIBILITY CRITERIA FOR DONORS OF WHOLE BLOOD AND BLOOD COMPONENTS</inline>
</tocItem>
<inline name="tocNum">1.</inline>
<inline name="tocHeading">ACCEPTANCE CRITERIA FOR DONORS OF WHOLE BLOOD AND BLOOD COMPONENTS...</inline>
<inline name="tocNum">1.1.</inline>
<inline name="tocHeading">Age and body weight of donors </inline>
<inline name="tocNum">1.2.</inline>
<inline name="tocHeading">Haemoglobin levels in donor's blood </inline>
<inline name="tocNum">1.3.</inline>
<inline name="tocHeading">Protein levels in donor's blood </inline>
<inline name="tocNum">1.4.</inline>
<inline name="tocHeading">Platelet levels in donor's blood </inline>
<inline name="tocNum">2.</inline>
<inline name="tocHeading">DEFERRAL CRITERIA FOR DONORS OF WHOLE BLOOD AND BLOOD COMPONENTS...</inline>
<inline name="tocNum">2.1.</inline>
<inline name="tocHeading">Permanent deferral criteria for donors of allogeneic donations </inline>
<inline name="tocNum">2.2.</inline>
<inline name="tocHeading">Temporary deferral criteria for donors of allogeneic donations </inline>
<inline name="tocNum">2.2.1.</inline>
<inline name="tocHeading">Infections </inline>
<inline name="tocHeading">Duration of deferral period </inline>
<inline name="tocNum">2.2.2.</inline>
<inline name="tocHeading">Exposure to risk of acquiring a transfusion-transmissible infection </inline>
<inline name="tocNum">2.2.3.</inline>
<inline name="tocHeading">Vaccination </inline>
<inline name="tocNum">2.2.4.</inline>
<inline name="tocHeading">Other temporary deferrals </inline>
<inline name="tocNum">2.3.</inline>
<inline name="tocHeading">Deferral for particular epidemiological situations </inline>
<inline name="tocNum">2.4.</inline>
<inline name="tocHeading">Deferral criteria for donors of autologous donations </inline>
<tocItem href="http://www.legislation.gov.uk/eudr/2004/33/annex/IV" level="2" class="schedule" period="#period1">
<inline name="tocNum">ANNEX IV</inline>
<inline name="tocHeading">STORAGE, TRANSPORT AND DISTRIBUTION CONDITIONS FOR BLOOD AND BLOOD COMPONENTS</inline>
</tocItem>
<inline name="tocNum">1.</inline>
<inline name="tocHeading">STORAGE </inline>
<inline name="tocNum">1.1.</inline>
<inline name="tocHeading">Liquid storage </inline>
<inline name="tocNum">1.2.</inline>
<inline name="tocHeading">Cryopreservation </inline>
<inline name="tocNum">2.</inline>
<inline name="tocHeading">TRANSPORT AND DISTRIBUTION </inline>
<inline name="tocNum">3.</inline>
<inline name="tocHeading">ADDITIONAL REQUIREMENTS FOR AUTOLOGOUS DONATIONS </inline>
<inline name="tocNum">3.1.</inline>
<inline name="tocHeading">Autologous blood and blood components must be clearly identified as...</inline>
<inline name="tocNum">3.2.</inline>
<inline name="tocHeading">Autologous blood and blood components must be labelled as required...</inline>
<tocItem href="http://www.legislation.gov.uk/eudr/2004/33/annex/V" level="2" class="schedule" period="#period2">
<inline name="tocNum">ANNEX V</inline>
<inline name="tocHeading">QUALITY AND SAFETY REQUIREMENTS FOR BLOOD AND BLOOD COMPONENTS</inline>
</tocItem>
<inline name="tocNum">1.</inline>
<inline name="tocHeading">THE BLOOD COMPONENTS </inline>
<inline name="tocNum">2.</inline>
<inline name="tocHeading">QUALITY CONTROL REQUIREMENTS FOR BLOOD AND BLOOD COMPONENTS </inline>
<inline name="tocNum">2.1.</inline>
<inline name="tocHeading">Blood and blood components must comply with the following technical...</inline>
<inline name="tocNum">2.2.</inline>
<inline name="tocHeading">Appropriate bacteriological control of the collection and manufacturing process must...</inline>
<inline name="tocNum">2.3.</inline>
<inline name="tocHeading">Member States must take all necessary measures to ensure that...</inline>
<inline name="tocNum">2.4.</inline>
<inline name="tocHeading">For autologous donations, the measures marked with an asterisk (*)...</inline>
</toc>
</coverPage>
<preface>
<longTitle>
<p>
<inline name="uppercase">Commission Directive 2004/33/EC</inline>
</p>
<p>of 22 March 2004</p>
<p>implementing Directive 2002/98/EC of the European Parliament and of the Council as regards certain technical requirements for blood and blood components</p>
<p>(Text with EEA relevance)</p>
</longTitle>
</preface>
<preamble>
<p>THE COMMISSION OF THE EUROPEAN COMMUNITIES,</p>
<p>Having regard to the Treaty establishing the European Community,</p>
<p>
Having regard to Directive 2002/98/EC of the European Parliament and of the Council of 27 January 2003 setting standards of quality and safety for the collection, testing, processing, storage and distribution of human blood and blood components and amending Directive 2001/83/EC
<noteRef href="#f00001" class="footnote" marker="1"/>
, and in particular points (b) to (g) of the second paragraph of Article 29 thereof,
</p>
<p>Whereas:</p>
<tblock>
<num>(1)</num>
<p>Directive 2002/98/EC lays down standards of quality and safety for the collection and testing of human blood and blood components, whatever their intended purpose, and for their processing, storage and distribution when intended for transfusion so as to ensure a high level of human health protection.</p>
</tblock>
<tblock>
<num>(2)</num>
<p>In order to prevent the transmission of diseases by blood and blood components and to ensure an equivalent level of quality and safety, Directive 2002/98/EC calls for the establishment of specific technical requirements.</p>
</tblock>
<tblock>
<num>(3)</num>
<p>
This Directive lays down those technical requirements, which take account of Council Recommendation 98/463/EC of 29 June 1998 on the suitability of blood and plasma donors and the screening of donated blood in the European Community
<noteRef href="#f00002" class="footnote" marker="2"/>
, certain recommendations of the Council of Europe, the opinion of the Scientific Committee for Medicinal Products and Medical Devices, the monographs of the European Pharmacopoeia, particularly in respect of blood or blood components as a starting material for the manufacture of proprietary medicinal products and recommendations of the World Health Organisation (WHO), as well as international experience in this field.
</p>
</tblock>
<tblock>
<num>(4)</num>
<p>Blood and blood components imported from third countries, including those used as starting material/raw material for the manufacture of medicinal products derived from human blood and human plasma, should meet the quality and safety requirements set out in this Directive.</p>
</tblock>
<tblock>
<num>(5)</num>
<p>With regard to blood and blood components collected for the sole purpose of, and exclusive use in, autologous transfusion (autologous donation), specific technical requirements should be laid down, as required by Article 2(2) of Directive 2002/98/EC. Such donations should be clearly identified and kept separate from other donations to ensure that they are not used for transfusion to other patients.</p>
</tblock>
<tblock>
<num>(6)</num>
<p>It is necessary to determine common definitions for technical terminology in order to ensure the consistent implementation of Directive 2002/98/EC.</p>
</tblock>
<tblock>
<num>(7)</num>
<p>The measures provided for in this Directive are in accordance with the opinion of the Committee set up by Directive 2002/98/EC,</p>
</tblock>
<p>HAS ADOPTED THIS DIRECTIVE:</p>
</preamble>
<body/>
</act>
</akomaNtoso>